External resources New England Journal of Medicine: Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2 trial) PMC: Switching between GLP-1 receptor agonists, rationale and practical guidance Endocrine Practice: Switching to tirzepatide from GLP-1 receptor agonists, clinical expectations PMC: The risk of vestibular disorders with semaglutide and tirzepatide In case I do not see you, good afternoon, good evening, and good night
This helps the body adjust to the medicine and reduces the chance of side effects
Researchers analyzed the SELECT trial data by looking at CV events in the first three to six months following semaglutide treatment for obesity, and found that the drug significantly lowered a patients MACE and CV mortality risk even before major weight loss occurred
The anti-obesity agent tesofensine is a prodrug, activating monoamines selectively in the important nervous system
Ozempic, a brand name for semaglutide, is more than just a medication